Company Performance Metrics
Salthill Pharma develops and clinically tests therapies for inflammatory and autoimmune diseases using a charity-based development model. The organization sources dormant or gifted pharmaceutical assets, particularly glucokinase activators such as AZD1656, and advances them through mechanistic and Phase II clinical studies. It focuses on activation
of regulatory T cells to modulate pathological inflammation and investigates applications in conditions such as COVID-19, cutaneous leishmaniasis, Graves’ disease, and immune-mediated kidney diseases. Salthill Pharma partners with originator pharmaceutical companies, academic institutions, and investors to structure licensing agreements and fund clinical programmes. It also publishes clinical and translational research and manages a pipeline of current and planned studies across multiple therapeutic areas.
